drugset / Trial / NCT00935467

Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects

NCT00935467

Phase 1 Completed 12 enrolled AstraZeneca
NaSingle-groupOpen-label

Summary

To characterize the steady-state pharmacokinetics (PK) of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects

Timeline

Start
2009-07
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 2.5 mg Oral